Skip to main content

Dr. Lee S. Stein, MD

Neurology (Neurology Physician)

  • Medicare participating

At a glance

Medical school
Georgia College of Eclectric Medicine and Surgery (1981)
Years since graduation
45
In the NPI registry since
2006
Medicare patients seen, 2024
564

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 1981Medical school: Georgia College of Eclectric Medicine and Surgery
  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Neurology Physician primary
    TN license MD16177

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Neurology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
564
Services billed
24,260
Patients’ average age
75
Most frequent Medicare services, 2023
ServiceTimesPatients
Injection, gadoterate meglumine, 0.1 ml10,55070
Established patient office or other outpatient visit, 30-39 minutes613362
Established patient office or other outpatient visit, 20-29 minutes186150
New patient office or other outpatient visit, 30-44 minutes9999
Mri scan of brain without contrast7574
Mri scan of brain before and after contrast6664
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less4511
Mri scan of upper spinal canal before and after contrast2625
Administration of chemotherapy into vein, 1 hour or less2311
Established patient office or other outpatient visit, 10-19 minutes2118

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 32 companies reported 194 payments worth $3,768 in total to this clinician.

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Nov 26, 2025Janssen Biotech, Inc.
Nov 26, 2025
Education
in-kind
$99.99
Dec 20, 2025Teva Pharmaceuticals USA, Inc.
Dec 20, 2025
Education
in-kind
$88.49
Apr 25, 2025Csl Behring
Apr 25, 2025
Education
Hizentra · Immunology · in-kind
$11.71
May 19, 2025Csl Behring
May 19, 2025
Education
Hizentra · Immunology · in-kind
$11.71
Jun 10, 2025Csl Behring
Jun 10, 2025
Education
Hizentra · Immunology · in-kind
$11.71
Jun 18, 2025Csl Behring
Jun 18, 2025
Education
Hizentra · Immunology · in-kind
$11.71
Sep 30, 2025Csl Behring
Sep 30, 2025
Education
Hizentra · Immunology · in-kind
$11.71

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Tennessee →

Industry-funded research

Named as a principal investigator on 10 industry-funded studies in 2025, from 6 companies. The companies reported $487,344 in research payments for these studies, mostly to the institutions running them.

  • A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
    Eisai Inc.
  • Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205
    Biogen, Inc.
  • A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
    Eli Lilly and Company · Active, not recruiting · NCT04437511
  • Ocrelizumab SC Phase III
    Genentech, Inc.
  • Ocrelizumab PPMS High Dose Study
    Genentech, Inc.
  • A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis
    Novartis Pharmaceuticals Corporation
  • Ocrevus Subcutaneous Study for Safety and Tolerability
    Genentech, Inc.
  • OCARINA I
    Genentech, Inc.
  • A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease
    Biogen, Inc.
  • A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
    ModernaTX, Inc. · Recruiting · NCT06735248

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Neurology clinicians in Cordova

Sources

NPI registry (CMS NPPES, November 2026; record last updated February 3, 2020), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1558392233. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.